AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
Lausanne, Switzerland, October 25, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases has been selected for an oral presentation in the late breaking session at the 11th annual Clinical Trials on Alzheimer's Disease (CTAD18) conference, taking place in Barcelona, Spain, from October 24th to 27th. The presentation with the title "Identification and characterization of small molecule clinical candidates targeting intracellular tau pathology" was selected for the late breaking communication session to be held at 3:45pm (CET) on Saturday, October 27th, and will be given by Dr. Sonia Poli, AC Immune's Head of Translational Science. Dr. Poli will report on progress in the characterization and development of the tau small molecule clinical candidate ACI-3024 in preparation for the first in human studies. In April 2018, AC Immune announced the selection of tau small molecule candid
[Read more]
| Impact snapshot | Event time: | ACIU | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACIU alerts
ACIU alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assayGlobeNewswire
- Target ALS Announces Second Round of 2020 Grant Recipients Focused on Discovering and Developing ALS BiomarkersPR Web
- AC Immune SA (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACIU/price-target/">NASDAQ: ACIU</a>) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.MarketBeat
- Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of DirectorsGlobeNewswire
- Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical OfficerGlobeNewswire
- More
ACIU
SEC Filings
- 1/14/21 - Form SC
- 11/23/20 - Form 6-K/A
- 11/23/20 - Form 6-K
- ACIU's page on the SEC website
- More